News
NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...
The new COVID-19 variant NB.1.8.1, known as Nimbus, is causing concern due to its subtle symptoms and high transmission rate.
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...
18d
Smithsonian Magazine on MSNSix Questions About Covid-19 Vaccines, AnsweredRecent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...
A major new study examining the 2023-2024 COVID-19 vaccines shows moderate protection that works best in the first few months but weakens considerably over time. The research, published in JAMA ...
When Robert F Kennedy Jr announced that the US would stop recommending covid-19 vaccines for healthy children and pregnancies ...
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results